At Tris, our commitment to advancing important innovations is fueled by a singular focus on enhancing care for patients. Learn more about our robust portfolio and pipeline in ADHD, pain, addiction and other diseases of the central nervous system: https://lnkd.in/eFe_3jEj #TogetherAtTris #innovation #biopharma
Tris Pharma
Pharmaceutical Manufacturing
Monmouth Junction, New Jersey 19,296 followers
Passion. Drive. Innovation.
About us
Tris Pharma, Inc. is a leading privately-owned biopharmaceutical company in the U.S. Our focus is on the development and commercialization of innovative medicines that address unmet patient needs and we have more than 150 U.S. and International patents including applications. We market several branded and generic products in the U.S; license our products in the U.S. and international markets and we have a robust pipeline of innovative products, that employ our proprietary science and technology, to meet patients’ needs in neuroscience and other therapeutic categories. Our science and technology make us unique, but it is our team members that set us apart; they are the engine that fuels Tris’ passion and innovation. The Tris team comprises of approximately 500 diverse individuals; one third of whom operate in the field throughout the U.S. while the other two-thirds work from Tris’ NJ operations. Tris colleagues understand the criticality of operating a successful business and take pride in the company’s success. But of equal importance to each member of the team is how we interact with one another on a daily basis. We believe in each other and we believe in respectful, open and honest communications to help support individual and team success. At Tris we strive to ensure our field and home office teams are connected and engaged. We listen to our teams in numerous ways including through our Diversity & Inclusion Committee and our Women’s Business Council to help to ensure every employee’s voice is heard. After all, it is our daily interactions with one another that build and sustain our culture which fuels our growth.
- Website
-
http://www.trispharma.com
External link for Tris Pharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Monmouth Junction, New Jersey
- Type
- Privately Held
- Founded
- 2000
Locations
-
Primary
Get directions
2031 US-130
Monmouth Junction, New Jersey 08852, US
-
Get directions
2033 Route 130
Monmouth Junction, NJ 08852, US
Employees at Tris Pharma
Updates
-
Our offices are buzzing again this week with teams reinvigorated by the #TrisSummerShutdown – with memories of how the week of downtime was spent still fresh! Here are a few snaps employees shared with us. #SummerAtTris #TogetherAtTris
-
OOO: It’s the #TrisSummerShutdown! Our offices are closed this week (July 1-5) for some much-needed rest and relaxation. We hope everyone enjoys the July 4th holiday! #SummerAtTris #TogetherAtTris #worklifebalance #companyculture
-
-
Go Team Tris! 🎉 Each day this week, employees came together for different celebrations themed around our company values of innovation, diversity, teamwork, leadership and caring. We hope everyone enjoyed some summer fun during our Tris Spirit Week. #SummerAtTris #TogetherAtTris #culture #teamwork
-
-
For National Account Manager Shiphrah Kamble, the collaborative and caring #culture at Tris gives everyone a common sense of purpose. Learn more about our company culture: https://lnkd.in/e3TFZBAR #TogetherAtTris
-
The first day of summer isn’t just the start of a new season – it could also be the perfect time to take the next step in your career. Learn more about what it’s like to work at Tris and view our current opportunities here: https://lnkd.in/eTZjBAwX #BiopharmaCareers #CareerOpportunities #TogetherAtTris
-
-
This year, Tris is closing its doors from July 1-5 to give everyone some well-deserved time away from the office to recharge. We asked employees about their plans for our “Summer Shutdown” in a recent company-wide survey, and here’s what they have planned. #SummerAtTris #TrisSummerShutdown
-
-
#NEWS: The U.S. FDA has approved our generic therapy for Duchenne muscular dystrophy. “Duchenne muscular dystrophy is a devastating rare disease, and with limited treatment options available there is a critical need for the greater accessibility that a generic therapy can bring,” said Ketan Mehta, founder and CEO at Tris Pharma. This approval is accompanied by the launch of our new generics subsidiary, Cranbury Pharmaceuticals. Read the press release: https://lnkd.in/erBZXmF8 #TogetherAtTris #raredisease
-
We’re excited to announce the launch of our new website! We’ve revamped our site to include the latest company developments, pipeline updates and highlight our unique #culture – all in a new, sleek design. Check it out now: https://lnkd.in/eX2Qi4j2 #TogetherAtTris
-
#NEWS: The U.S. FDA has approved a new non-stimulant medication for the treatment of #ADHD in pediatric patients six years and older. Read the press release: https://lnkd.in/edNsMtHY #TogetherAtTris